What is the use of Visanne (Dienogest) 2 mg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Visanne (Dienogest) 2 mg is primarily used to treat endometriosis, a condition where tissue similar to the uterine lining grows outside the uterus. The typical dosage is one 2 mg tablet taken daily without interruption. Dienogest works by reducing estrogen levels and suppressing the growth of endometrial tissue, which helps alleviate endometriosis symptoms such as pelvic pain, painful periods, and pain during intercourse.

Key Points

  • Treatment is usually long-term, often continuing for months or years as needed for symptom control.
  • Patients should take the tablet at approximately the same time each day with water, with or without food.
  • Common side effects may include headaches, breast discomfort, mood changes, and irregular bleeding, particularly during the first months of treatment.
  • While Visanne is not a contraceptive, it does suppress ovulation in many women. However, non-hormonal contraception methods are recommended if pregnancy prevention is needed.
  • Improvement in symptoms is typically noticed within a few months of starting treatment, though individual responses vary. According to the most recent study 1, dienogest (2 mg/day) is comparable to the combined oral contraceptive pill (COC) Yasmin for the relief of endometriosis-associated pelvic pain and improvement in health-related quality of life.

Safety and Efficacy

  • The study 1 found that dienogest was associated with fewer side effects and had a better safety and tolerability profile than COC.
  • Another study 2 confirmed that dienogest is safe and effective for the treatment of endometriosis in a large Korean cohort.
  • The Visanne Post-approval Observational Study (VIPOS) 3, 4 provided real-world insights into endometriosis management in Europe and found no safety signal regarding anemia for dienogest users, whereas a slight increase in depression risk cannot be excluded.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.